C Lonnroth
Overview
Explore the profile of C Lonnroth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kodeda K, Asting A, Lonnroth C, Derwinger K, Wettergren Y, Nordgren S, et al.
Int J Oncol
. 2012 Jul;
41(4):1397-404.
PMID: 22825718
Several factors determine overall outcome and possible local recurrence after curative surgery for rectal carcinoma. Surgical performance is usually believed to be the most pertinent factor, followed by adjuvant oncological...
2.
Lonnroth C, Gelin J, Lundholm K
Int J Oncol
. 2011 May;
5(2):329-36.
PMID: 21559593
Increased production of IL-6 in tumor-bearing mice occured in a variety of host-tissues including tumor tissue. Elevated IL-6 transcription in tumor-bearing mice occured in the tumor, liver, kidney and the...
3.
Lonnroth C, Svaninger G, Gelin J, Cahlin C, Iresjo B, Cvetkovska E, et al.
Int J Oncol
. 2011 May;
7(6):1405-13.
PMID: 21552980
Tumor-bearing mice with two different locally growing malignant tumors (epithelial like, MCG 101; malignant melanoma, K1735-M2) were used to evaluate the putative role of prostaglandins for survival and local tumor...
4.
Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, et al.
Ann Oncol
. 2006 Mar;
17(5):842-7.
PMID: 16524972
Background: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found...
5.
Lagerstedt K, Kressner U, Lonnroth C, Nordgren S, Lundholm K
Int J Oncol
. 2005 Nov;
27(6):1707-15.
PMID: 16273227
The role of p53 mutations in disease progression and survival of colorectal cancer is unclear, since numerous studies have reported different conclusions. However, few reports, if any, have evaluated disease...
6.
Wang W, Andersson M, Lonnroth C, Svanberg E, Lundholm K
J Exp Clin Cancer Res
. 2005 Jun;
24(1):99-107.
PMID: 15943039
Previous studies in our laboratory have suggested that prostaglandin (PG) E2 is involved in anorexia/cachexia development in MCG 101 tumor-bearing mice. However, the role of COX pathways in the pathogenesis...
7.
Wang W, Lonnroth C, Svanberg E, Lundholm K
Cancer Res
. 2001 Jun;
61(12):4707-15.
PMID: 11406541
Evidence suggests that cytokines in the central nervous system are mediators behind anorexia in tumor-bearing hosts. We have therefore evaluated, by immunohistochemical image analyses, time course changes of interleukin (IL)-1beta,...
8.
Forslund A, Lonnroth C, Andersson M, Brevinge H, Lundholm K
J Clin Oncol
. 2001 Jun;
19(11):2829-36.
PMID: 11387354
Purpose: To compare p53 alterations in survivors and nonsurvivors after surgery for colorectal cancer. Patients And Methods: Twenty-nine potentially cured patients with colorectal carcinoma, without recurrent disease for more than...
9.
Lonnroth C, Andersson M, Lundholm K
Int J Oncol
. 2001 Apr;
18(5):929-37.
PMID: 11295037
It is well-recognized that cycloogygenase inhibitors attenuate tumor growth in tumor models, although underlying mechanisms are unclear. In the present study we report that indomethacin retards MCG-101 tumor growth on...
10.
Yang Y, Forslund A, Remotti H, Lonnroth C, Andersson M, Brevinge H, et al.
Cancer
. 2001 Mar;
91(4):727-36.
PMID: 11241240
Background: The appearance of p53 mutations in colorectal carcinoma was determined, independent of differentiation and tumor stage of the primary tumors, in relation to the survival of patients who were...